Keywords
| 1. |
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219-31. ![]() [PUBMED] |
| 2. |
Kovacs G, Wood C. The current status of polycystic ovary syndrome. Aust N Z J Obstet Gynaecol 2001;41:65-8. ![]() [PUBMED] |
| 3. |
Guzick D. Polycystic ovary syndrome: Symptomatology, pathophysiology, and epidemiology. Am J Obstet Gynecol 1998;179:S89-93. ![]() [PUBMED] |
| 4. |
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7. ![]() [PUBMED] |
| 5. |
Kitzinger C, Willmott J. 'The thief of womanhood': Women's experience of polycystic ovarian syndrome. Soc Sci Med 2002;54:349-61. ![]() [PUBMED] |
| 6. |
Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: Progress and paradoxes. Recent Prog Horm Res 2001;56:295-308. ![]() [PUBMED] |
| 7. |
Lanzone A, Fulghesu AM, Andreani CL, Apa R, Fortini A, Caruso A, et al. Insulin secretion in polycystic ovarian disease: Effect of ovarian suppression by GnRH agonist. Hum Reprod 1990;5:143-9. ![]() [PUBMED] |
| 8. | |
| 9. |
Badawy A, Mosbah A, Shady M. Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: A prospective randomized trial. Fertil Steril 2008;89:1209-12. ![]() [PUBMED] |
| 10. |
Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002;77:91-7. ![]() [PUBMED] |
| 11. |
Requena A, Herrero J, Landeras J, Navarro E, Neyro JL, Salvador C, et al. Use of letrozole in assisted reproduction: A systematic review and meta-analysis. Hum Reprod Update 2008;14:571-82. ![]() [PUBMED] |
| 12. |
Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril 2002;77:1128-35. ![]() [PUBMED] |
| 13. | |
| 14. |
Pieper GM, Siebeneich W. Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. J Cardiovasc Pharmacol 1998;32:101-5. ![]() [PUBMED] |
| 15. |
Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril 2006;85:277-84. ![]() [PUBMED] |
| 16. |
Riyahinezhad S, Tehrani HG, Movahedi M, Soltani N, Haghighat F. The effectiveness of using of N acetyl cysteine together with clomiphene citrate on ovulation indication in the patients with polycystic ovary syndrome referred to Isfahan reproduction and infertility center, 2013. J Sci Res Dev 2015;2:210-4. ![]() |
| 17. |
Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril 2005;83:367-70. ![]() [PUBMED] |
| 18. | |
| 19. | |
| 20. |
De Mattia G, Bravi MC, Laurenti O, Cassone-Faldetta M, Proietti A, De Luca O, et al. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia 1998;41:1392-6. ![]() [PUBMED] |
| 21. |
Odetti P, Pesce C, Traverso N, Menini S, Maineri EP, Cosso L, et al. Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes. Diabetes 2003;52:499-505. ![]() [PUBMED] |